Some clinical trials for these logic-gated CAR T cells are ongoing, such as EVEREST-1, which is evaluating A2B530 in tumors with enhanced CEA expression but loss of HLA-A*A02 expression (colon, pancreatic, and NSCLC tumors; NCT05736731). The gene discussed is HLA-A; the disease is non-small cell lung carcinoma.